For additional specific information related to nationally authorised products (including MRP/DCP): CMDh practical guidance for Marketing Authorisation Holders of nationally authorised products (incl. MRP/DCP) in relation to the Art. 5(3) Referral on Nitrosamines (July 2023) [Tracked]Template for nitrosamine risk evaluation in marketing authorisation applications
